Building biotech solutions for diseases of the developing world. Global Health Council June 1, 2006 Washington, DC. Wendy Taylor Founder and Vice President Strategy and Operations. BVGH’s Fundamental Premise.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Global Health Council
June 1, 2006
Founder and Vice President
Strategy and Operations
The innovative drive and expertise of the biotech industry are integral to the mission of saving lives and treating diseases that afflict the world's poorest people.
BVGH is breaking down barriers that hinder development of new vaccines, drugs and diagnostics to treat the urgent medical needs of the developing world.
Respiratory syncitial virus
Global pharmaceutical sales focus on the fastest-growing segments
Rest of the world
SE Asia + China
Total >$400 billion
75% in 12 countries
Profits by year and market for BCG boost (2013 – 2030)
Public mkt demand
Private mkt demand
Upfront facility costs ($250MM) ((infrastructure), adjusted for timing of investment(1)
Represents all costs ($638MM) incurred for R&D, adjusted for timing of investments(2)
Source: BVGH/BCG analysis NOTE: Estimates for potential analysis only; information not provided by industry.
Over a million lives could be saved each year by novel TB vaccines at low cost/DALY
Deaths (millions per year)
Cost per DALY averted in Africa
- BCG Replace ($6-10)
- BCG Boost ($21-26)
- Prime + Boost ($21-23)
Source: BVGH TB Vaccine Business Case
to be addressed
Building biotech solutionsfor diseases of the developing world
High level assessment criteria
Global burden of disease in DALYs and deaths
Adequacy of current solutions proxied
by mortality CAGR. Qualitative scan of
gaps in current drugs, vaccines, & diagnostics
Quantitative scan of publication activity, state of
pipeline, and NIH funding; review of key
publications, partic. rel. to targets
Match needs w/ key biotech assets – Rx, Dx, Vx
discovery; preclinical and clinical product
First pass review of a) hybrid and dual/use
markets; b) other pull and push funding